PURPOSE: To report 11 cases of autosomal recessive vitelliform macular dystrophy and to compare their molecular findings and phenotypic characteristics with those of patients with the more common and well-described dominant form of the disease. METHODS: Blood samples were obtained from 435 unrelated individuals with a clinical diagnosis of vitelliform macular dystrophy and screened for mutations in the coding sequences of BEST1. Medical records and retinal photographs of selected patients were reviewed. RESULTS: Nine of the 435 probands were found to have 2 plausible disease-causing variations in BEST1, while 198 individuals were found to have heterozygous variations compatible with autosomal dominant inheritance. Inheritance phase was determined in three of the recessive families. Six novel disease-causing mutations were identified among these recessive patients: Arg47Cys, IVS7-2A>G, IVS7+4G>A, Ile205del12ATCCTGCTCCAGAG, Pro274Arg, and Ile366delCAGGTGTGGC. Forty-four novel disease-causing mutations were identified among the patients with presumed autosomal dominant disease. The phenotype of patients with recessive alleles for BEST1 ranged from typical vitelliform lesions to extensive extramacular deposits. CONCLUSION: The authors provide evidence that two abnormal BEST1 alleles, neither of which causes macular disease alone, can act in concert to cause early-onset vitelliform macular dystrophy.
PURPOSE: To report 11 cases of autosomal recessive vitelliform macular dystrophy and to compare their molecular findings and phenotypic characteristics with those of patients with the more common and well-described dominant form of the disease. METHODS: Blood samples were obtained from 435 unrelated individuals with a clinical diagnosis of vitelliform macular dystrophy and screened for mutations in the coding sequences of BEST1. Medical records and retinal photographs of selected patients were reviewed. RESULTS: Nine of the 435 probands were found to have 2 plausible disease-causing variations in BEST1, while 198 individuals were found to have heterozygous variations compatible with autosomal dominant inheritance. Inheritance phase was determined in three of the recessive families. Six novel disease-causing mutations were identified among these recessive patients: Arg47Cys, IVS7-2A>G, IVS7+4G>A, Ile205del12ATCCTGCTCCAGAG, Pro274Arg, and Ile366delCAGGTGTGGC. Forty-four novel disease-causing mutations were identified among the patients with presumed autosomal dominant disease. The phenotype of patients with recessive alleles for BEST1 ranged from typical vitelliform lesions to extensive extramacular deposits. CONCLUSION: The authors provide evidence that two abnormal BEST1 alleles, neither of which causes macular disease alone, can act in concert to cause early-onset vitelliform macular dystrophy.
Authors: L Zhao; S Grob; R Corey; M Krupa; J Luo; H Du; C Lee; G Hughes; J Lee; J Quach; J Zhu; P X Shaw; I Kozak; K Zhang Journal: Eye (Lond) Date: 2012-03-16 Impact factor: 3.775
Authors: Christine N Kay; Michael D Abramoff; Robert F Mullins; Tyson R Kinnick; Kyuongmoo Lee; Mari E Eyestone; Mina M Chung; Elliott H Sohn; Edwin M Stone Journal: Arch Ophthalmol Date: 2011-11-14
Authors: Karina E Guziewicz; Divya Sinha; Néstor M Gómez; Kathryn Zorych; Emily V Dutrow; Anuradha Dhingra; Robert F Mullins; Edwin M Stone; David M Gamm; Kathleen Boesze-Battaglia; Gustavo D Aguirre Journal: Prog Retin Eye Res Date: 2017-01-19 Impact factor: 21.198
Authors: Adrian T Fung; Suzanne Yzer; Naomi Goldberg; Hao Wang; Michael Nissen; Alfonso Giovannini; Joanna E Merriam; Elena N Bukanova; Carolyn Cai; Lawrence A Yannuzzi; Stephen H Tsang; Rando Allikmets Journal: Retina Date: 2015-04 Impact factor: 4.256
Authors: Michael D Abràmoff; Robert F Mullins; Kyungmoo Lee; Jeremy M Hoffmann; Milan Sonka; Douglas B Critser; Steven F Stasheff; Edwin M Stone Journal: Invest Ophthalmol Vis Sci Date: 2013-05-01 Impact factor: 4.799
Authors: Mital Shah; Suzanne Broadgate; Morag Shanks; Penny Clouston; Jing Yu; Robert E MacLaren; Andrea H Németh; Stephanie Halford; Susan M Downes Journal: JAMA Ophthalmol Date: 2020-05-01 Impact factor: 7.389